Therapeutics, Inc. is a DNA Interference (DNAi®)-based
biopharmaceutical company that is leveraging its novel and proprietary
nucleic acid-based interfering technology, DNAi®, to advance a
next generation of therapies for patients with cancer and other complex
ProNAi is actively
seeking partners and licensing opportunities for further development of
its promising DNAi® pipeline, on the strength of very
compelling preclinical results to date.